Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 4, pp 24–27 | Cite as

Schwerpunkt triple-negatives Mammakarzinom

Die systemische Behandlung des triple-negativen Mammakarzinoms

  • Julia Landin
  • Marcus VetterEmail author
schwerpunkt
  • 11 Downloads

Im Vergleich zu anderen Mammakarzinom-Subtypen ist die Prognose des triple-negativen Mammakarzinoms eher schlecht. Standardtherapie ist nach wie vor die Chemotherapie. Hoffnungen machen jetzt neuere Behandlungsansätze wie die PARP- oder Checkpointinhibiton.

Literatur

  1. 1.
    Liedtke C et al. Response to neoadjuvant therapy and long-term survival in patients with TNBC. J Clin Oncol. 2008;26(8):1275–81CrossRefGoogle Scholar
  2. 2.
    von Minckwitz G et al. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol. 2012;30(15):1796–804CrossRefGoogle Scholar
  3. 3.
    Morante Z et al. Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer. SABCS. 2018;Abstr GS2-05Google Scholar
  4. 4.
    Denkert C et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–91CrossRefGoogle Scholar
  5. 5.
    von Minckwitz G. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;(7):747-56Google Scholar
  6. 6.
    Keaton Litton J et. al. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). J Clin Oncol. 2018;36(15_suppl):Abstr 508CrossRefGoogle Scholar
  7. 7.
    Keller AM et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22(19):3893–901CrossRefGoogle Scholar
  8. 8.
    Cortes J et al. EMBRACE Investigators: Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23CrossRefGoogle Scholar
  9. 9.
    Tutt A et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018; 24(5):628–37CrossRefGoogle Scholar
  10. 10.
    Bardia A et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741–51CrossRefGoogle Scholar
  11. 11.
    Robson M et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523–33CrossRefGoogle Scholar
  12. 12.
    Litton JK et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753–63CrossRefGoogle Scholar
  13. 13.
    Schmid P et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. IMpassion 30 Trial. N Engl J Med. 2018;379(22):2108–21CrossRefGoogle Scholar
  14. 14.
    Vinayak S et al. TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. J Clin Oncol. 2018;36(15_suppl):Abstr 1011CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Medizinische Onkologie und gynäkologisches TumorzentrumUniversitätsspital BaselBaselSchweiz

Personalised recommendations